Target Name: LOC105370286
NCBI ID: G105370286
Review Report on LOC105370286 Target / Biomarker Content of Review Report on LOC105370286 Target / Biomarker
LOC105370286
Other Name(s): LOC105370286 variant X5 | Uncharacterized LOC105370286, transcript variant X1 | LOC105370286 variant X1 | LOC105370286 variant X2 | uncharacterized LOC105370286 | Uncharacterized LOC105370286, transcript variant X2 | Uncharacterized LOC105370286, transcript variant X4 | Uncharacterized LOC105370286, transcript variant X5 | Uncharacterized LOC105370286, transcript variant X3 | LOC105370286 variant X3 | LOC105370286 variant X4

LOC105370286: A Potential Drug Target or Biomarker

LOC105370286 (LOC105370286 variant X5) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the LOC105370286 gene family, which has been implicated in a number of cellular processes, including cell signaling, DNA replication, and stress response.

Recent studies have identified LOC105370286 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because the protein is involved in a number of cellular processes that are disrupted in these conditions, and may provide a target for drugs that can restore normal cellular function.

One of the key reasons for the potential of LOC105370286 as a drug target is its involvement in cell signaling. LOC105370286 is a member of the T-cell receptor (TCR) signaling pathway, which is critical for the development and activation of T cells, a crucial immune cell that play a key role in fighting off infections and diseases. In T-cells, LOC105370286 is involved in the development of clonal expansion, survival, and proliferation, as well as in the regulation of cell differentiation.

Disruptions in TCR signaling have been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. LOC105370286 may therefore be a useful target for drugs that can restore normal TCR signaling. For example, one class of drugs that have been shown to be effective in treating cancer is known as checkpoint inhibitors. These drugs work by inhibiting the activity of a protein called PD-L1, which is a critical regulator of immune response and has been implicated in the development of many cancers. By blocking PD-L1, checkpoint inhibitors can restore normal immune function and help to treat cancer.

LOC105370286 is also involved in DNA replication, another critical process that is disrupted in many diseases. In addition, LOC105370286 is involved in stress response, which is a critical aspect of cellular function that is often disrupted in conditions such as stress, aging, and disease.

In addition to its involvement in cell signaling, LOC105370286 may also be a useful biomarker for a variety of diseases. For example, LOC105370286 has been shown to be elevated in the blood of people with a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, LOC105370286 has been shown to be elevated in the urine of people with urological cancer, a common form of cancer that can be difficult to diagnose and treat.

Overall, LOC105370286 is a protein that is involved in a number of critical cellular processes that are disrupted in many diseases. As a result, it may be a valuable drug target or biomarker for a variety of conditions. Further research is needed to fully understand the role of LOC105370286 in cellular function and disease.

Protein Name: Uncharacterized LOC105370286

The "LOC105370286 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105370286 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105370302 | LOC105370311 | LOC105370312 | LOC105370321 | LOC105370324 | LOC105370328 | LOC105370355 | LOC105370359 | LOC105370384 | LOC105370399 | LOC105370420 | LOC105370429 | LOC105370438 | LOC105370452 | LOC105370455 | LOC105370470 | LOC105370476 | LOC105370481 | LOC105370497 | LOC105370500 | LOC105370504 | LOC105370507 | LOC105370519 | LOC105370529 | LOC105370536 | LOC105370544 | LOC105370546 | LOC105370547 | LOC105370548 | LOC105370549 | LOC105370557 | LOC105370572 | LOC105370574 | LOC105370575 | LOC105370577 | LOC105370579 | LOC105370582 | LOC105370614 | LOC105370616 | LOC105370617 | LOC105370619 | LOC105370627 | LOC105370645 | LOC105370660 | LOC105370706 | LOC105370721 | LOC105370740 | LOC105370819 | LOC105370826 | LOC105370832 | LOC105370834 | LOC105370841 | LOC105370842 | LOC105370843 | LOC105370844 | LOC105370845 | LOC105370846 | LOC105370852 | LOC105370878 | LOC105370891 | LOC105370892 | LOC105370905 | LOC105370906 | LOC105370913 | LOC105370914 | LOC105370941 | LOC105370955 | LOC105370965 | LOC105370978 | LOC105370980 | LOC105370982 | LOC105370988 | LOC105370991 | LOC105370995 | LOC105371002 | LOC105371006 | LOC105371060 | LOC105371061 | LOC105371068 | LOC105371069 | LOC105371072 | LOC105371081 | LOC105371082 | LOC105371097 | LOC105371114 | LOC105371116 | LOC105371160 | LOC105371164 | LOC105371230 | LOC105371268 | LOC105371269 | LOC105371274 | LOC105371275 | LOC105371276 | LOC105371278 | LOC105371279 | LOC105371308 | LOC105371347 | LOC105371356 | LOC105371371